Navigating China's 30-Day IND Fast Track: A Strategic Guide for Overseas Drug Developers

Why This Matters Now

For decades, overseas drug developers eyeing the Chinese market faced a familiar bottleneck: the 60-day IND review timeline. While the 2020 Drug Registration Administration Measures brought the "silent approval" system — where an IND is deemed approved if CDE doesn't respond within 60 working days — the practical average hovered around 50 working days. That's roughly 10 weeks of waiting before a single patient can be enrolled.

In September 2025, NMPA changed the game with Announcement No. 86, introducing a 30-day IND review pathway for qualifying innovative drugs. Then in January 2026, Announcement No. 3 expanded the scope to cover clinically urgent overseas-approved drugs — including generics. Together, these two announcements represent the most significant regulatory acceleration since the 60-day silent approval system itself.

But here's the catch: the 30-day pathway isn't a simple "apply and get approved faster" mechanism. It restructures the entire workflow — front-loading ethics reviews, PI engagement, and risk management before submission. For overseas developers unfamiliar with China's clinical trial ecosystem, this creates both opportunity and risk.

This article provides a comprehensive, practitioner-oriented guide: who qualifies, what to prepare, how to navigate the process, and — critically — when the 30-day pathway might actually slow you down.

I. Who Qualifies? Four Pathways to the 30-Day Fast Track

The 30-day pathway is not a single lane — it's a multi-lane highway with four distinct entry points.

Pathway 1: National Full-Chain Support — The "VIP Lane"

This pathway covers drugs designated under the national full-chain policy framework for innovative drug development — drugs with evident clinical value that have received top-level government recognition. Think of it as the fastest lane, but with the highest barrier to entry.

Eligibility threshold: The drug must appear on the national-level designation list. As of mid-2026, the Implementation Plan has not yet been published, meaning this pathway is currently not operational. Both Beijing CDE and Yangtze River Delta CDE have confirmed they cannot accept applications under this category until the plan is formally released.

Who should watch this: Companies with drugs supported by national major new drug creation programs or included in national strategic emerging industry development plans. Monitor NMPA and CDE announcements for the Implementation Plan publication.

Pathway 2: Starlight & Care Plans — Children and Rare Diseases

This pathway specifically serves two underserved populations: children and patients with rare diseases. CDE has established dedicated programs — the "Starlight Plan" for pediatric anti-cancer drugs and the "Care Plan" for rare disease drugs — to encourage development in these areas.

Eligibility threshold: The drug must first be included in and publicly announced by CDE under the relevant plan. This is a sequential process — you cannot apply for both plan inclusion and 30-day pathway concurrently. The public announcement serves as your proof document when submitting the IND.

Note on TCM: Announcement No. 86 specifies that the scope of TCM innovative drugs will be separately defined and published. As of mid-2026, this scope has not been released, leaving TCM developers temporarily limited to the 60-day pathway or Pre-IND preparation strategies.

Pathway 3: Global Synchronous Development (MRCT) — The International Fast Lane

This is the pathway most relevant to overseas developers. It covers Class 1 innovative drugs being developed under a global synchronous strategy, including international multi-center clinical trials (MRCT). NMPA explicitly encourages Chinese researchers to participate earlier and more deeply in global drug development — and this pathway is the regulatory mechanism to enable that.

Proof requirements: This pathway is not "claim and qualify." You must submit substantive evidence, such as:

• Overseas IND acceptance number or approval letter (the strongest supporting evidence)

• Global development timeline demonstrating genuine synchronous planning

• If no overseas IND approval yet: pre-IND communication records with overseas regulators, CDP containing an MRCT plan, or documentation of overseas trial initiation (site/ethics)

CDE reserves the right to verify all claims. During review and after approval, CDE may request supplementary evidence of genuine global synchronous execution. Strategic arbitrage — claiming MRCT without real evidence — is not viable.

Pathway 4: Clinically Urgent Overseas-Approved Drugs — The New Frontier

Announcement No. 3 (January 2026) introduced a game-changing expansion: clinically urgent overseas-approved drugs can now access the 30-day pathway — and this category is NOT limited to Class 1 innovative drugs. Both originator drugs and generics qualify, provided there is genuine clinical urgency.

Mandatory pre-requisite: Before submitting any IND under this pathway, you must conduct a Category I (highest-priority) communication meeting with CDE and reach consensus. CDE will evaluate whether the drug meets the "clinically urgent" threshold and whether clinical trials are necessary or can be waived.

This pathway also introduces a potential shortcut: if CDE determines during communication that clinical trials can be waived based on existing overseas data, you can directly file a marketing authorization application — bypassing the IND entirely.

Additional documentation required for this pathway includes:

• Complete overseas clinical data package (all clinical data plus necessary CMC, non-clinical, and other study data)

• Post-marketing clinical application and safety monitoring reports from the country of origin

• Cross-racial/regional benefit-risk assessment analysis

• Post-import risk control plan (including post-marketing clinical study commitments)

• Domestic MRCT data (encouraged, if available)

II. The 30-Day IND Process: Step by Step

The 30-day pathway fundamentally restructures the IND submission workflow. Unlike the conventional 60-day route — where IND review and site/ethics preparation run concurrently — the 30-day route requires significant upfront coordination before you even submit. Here's the complete workflow:

Step 1: Pre-IND Communication with CDE — Schedule a formal communication meeting with CDE before submission. This is not optional for Pathway 4 and is strongly recommended for all pathways. The goal: identify potential review concerns, clarify data requirements, and establish mutual understanding of the development strategy.

Step 2: Lock Your PI — Identify and engage the Principal Investigator early. The PI must review the clinical trial protocol (CTP), sign the Commitment Letter, and co-sign the DRMP with the sponsor. Without PI signature on these two documents, you cannot enter the 30-day pathway.

Step 3: Ethics Front-Loading — Initiate ethics communication with the lead site's Ethics Committee before IND submission. You do NOT need a formal ethics approval at submission time — a conditional approval letter, acceptance letter, or review schedule confirmation is sufficient. After receiving the clinical trial notification, you then convert this to a formal ethics approval.

Step 4: Submit IND (Mark "30-Day Pathway") — File the IND application with all standard CTD Modules 1–5 plus the additional 30-day pathway materials. Clearly indicate on the application form that you are applying under the 30-day pathway. CDE will make an acceptance decision within 5 working days.

Step 5: CDE Acceptance Decision (5 Working Days) — If accepted: the 30-day review clock starts. If not accepted: the application does NOT automatically convert to a 60-day review. You must correct deficiencies and resubmit — you can choose either 30-day or 60-day on resubmission.

Step 6: 30-Day Review Period — CDE completes review within 30 working days. Practical experience shows average review time is approximately 20 working days. Most reviews proceed without inquiry questions. If CDE identifies complex issues requiring expert consultation, they will notify you by the 20th working day, and the overall timeline extends to 60 working days (elapsed time counted within 60).

Step 7: Approval & 12-Week Launch — Upon approval, convert conditional ethics approval to formal ethics approval. You must enroll the first subject within 12 weeks (84 calendar days) of approval. This is a hard commitment — failure to fulfill may jeopardize future 30-day pathway eligibility.

III. What You Need Beyond CTD Modules 1–5

The standard IND submission follows the CTD format (Modules 1–5). The 30-day pathway adds a mandatory layer of supplementary documentation — every item below is a hard requirement, and missing any one may result in non-acceptance.

For Pathway 4 (clinically urgent overseas-approved drugs), the documentation burden is heavier because CDE needs to evaluate whether existing overseas data can support a Chinese application:

IV. Critical Points Overseas Developers Must Understand

Hard Constraints That Cannot Be Negotiated

12-Week Launch Commitment Is Non-Negotiable. Upon approval, the first subject must sign the informed consent form within 12 weeks (84 calendar days). This is not aspirational — it is a binding commitment. Failure to deliver may result in denial of future 30-day pathway applications. For overseas developers, this means clinical supply import clearance, EDC setup, and human genetic resource office approvals must all be pre-planned to fit within this window.

PI Signature Is a Hard Threshold. The Commitment Letter and DRMP both require PI signature. If you haven't identified and engaged a willing PI, you cannot enter the 30-day pathway. This is particularly relevant for overseas developers who may not have established relationships with Chinese investigators.

Non-Acceptance Does Not Auto-Convert to 60-Day. If CDE determines within 5 working days that your application doesn't meet 30-day pathway requirements, it is simply not accepted. You must address the deficiencies and resubmit. You may choose 30-day or 60-day on resubmission, but there is no automatic fallback.

Starlight/Care Plan Inclusion Must Come First. You cannot simultaneously apply for plan inclusion and the 30-day pathway. The sequence is: apply for inclusion → receive public announcement → then apply for 30-day pathway using the announcement as proof.

Operational Bottlenecks to Anticipate

CTP Finalization Is the #1 Timeline Killer. The clinical trial protocol must be finalized and agreed with the PI and Ethics Committee before submission. In practice, many sponsors experience multiple CTP revisions leading to repeated ethics reviews. For overseas developers, translating and adapting protocols for Chinese regulatory expectations adds another layer of complexity.

Clinical Supply Import for MRCT. When the investigational product is manufactured overseas, import clearance procedures must be planned well in advance. The 12-week launch window leaves no room for customs or regulatory delays on drug shipment.

Human Genetic Resource (HGR) Compliance. MRCTs involving Chinese subjects may trigger HGR office approval or filing requirements. These administrative processes have their own timelines and must be integrated into the 12-week launch plan.

Site Contract Negotiation. Signing clinical trial agreements with sites can be time-consuming, especially without prior relationships. Sponsors with established partnerships and template contracts will move faster.

Strategic Recommendations

• Start preparation at least 2 months before target submission date: visit sites, meet the lead PI, hold an internal kick-off meeting, and define critical path milestones.

• For protocols involving biomarkers: confirm central laboratory capability (reagents, validated assays) early.

• Build EDC in advance: at minimum, have a CTP summary ready so EDC can be operational within 12 weeks of approval.

• Conduct a Pre-IND meeting with CDE — even for Pathways 1–3 where it's not mandatory. Early communication prevents late-stage surprises.

• Choose sites with 30-day pathway experience. Many major clinical institutions have now published standardized workflows for this pathway. Working with experienced sites significantly reduces friction.

V. 30-Day vs 60-Day: When Faster Isn't Better

This is perhaps the most important section of this guide. The 30-day pathway is a powerful tool — but it is not universally superior to the 60-day pathway. The decision must be based on two dimensions, not just one.

Dimension 1: Can You Launch Within 12 Weeks?

This is the most obvious consideration. The 30-day pathway requires a binding commitment to launch within 12 weeks. If your team cannot reliably deliver on this timeline — due to PI availability, site readiness, supply chain logistics, or regulatory filings — the 60-day pathway provides a safer alternative with no such constraint.

Dimension 2: Can Your Team Coordinate Efficiently Enough?

This dimension is less obvious but equally critical. The 30-day pathway front-loads all site initiation and ethics work before IND submission. The 60-day pathway allows these activities to proceed concurrently during the review period. The fundamental question is:

"Can your team complete all preliminary work (PI engagement, CTP finalization, ethics review, site contracts, supply import) faster than the time saved by cutting review from 60 to 30 days?"

If the answer is yes, then the 30-day pathway delivers genuine acceleration.

If the answer is uncertain, then the front-loading phase may take longer than the 6 weeks saved in review. In this scenario, the 60-day pathway's concurrent approach may actually result in a shorter total timeline.

Decision Framework

Go 30-Day when: PI is locked and willing to sign, CTP is near-final, ethics front-loading is underway, team has strong Chinese clinical operations experience, and you can confidently commit to 12-week launch. In this scenario, the 30-day pathway delivers approximately 6 weeks of genuine timeline acceleration.

Go 60-Day when: PI is not yet identified, CTP needs significant adaptation, team lacks Chinese operational experience, or launch timeline is uncertain. The concurrent approach allows review and site preparation to proceed in parallel, which may yield a shorter total timeline despite the longer review period.

"Choosing the appropriate pathway is more important than choosing the faster one. The 30-day pathway is designed for sponsors with strong execution capability and genuine rapid-launch needs — do not pursue speed for the sake of speed."

VI. Which Companies Should Pursue the 30-Day Pathway?

Disclaimer: This article is based on NMPA announcements, CDE policy interpretations, and practitioner experience as of mid-2026. Regulatory details may evolve with subsequent guidance documents. Always refer to CDE's official website (cde.org.cn) for the latest authoritative information.